Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 3Recurrence 2Myasthenia Gravis 2Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1

Interventions

Dexamethasone 110Cyclophosphamide 99Melphalan 91Bortezomib 68Peripheral Blood Stem Cell Transplantation 63Lenalidomide 57fludarabine phosphate 55Busulfan 53Filgrastim 50Antilymphocyte Serum 38Tacrolimus 37Thalidomide 36Radiotherapy 36Mycophenolic Acid 32fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Prednisone 21Whole-Body Irradiation 20Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 14Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Plasma Cell × inebilizumab × Clear all
NCT01861340 2018-09-10

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
20 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡